BioNTech SE/BNTX

$86.48

-0.87%
-
1D1W1MYTD1YMAX

About BioNTech SE

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Ticker

BNTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Ugur Sahin

Employees

6,133

Headquarters

Mainz, Germany

BioNTech SE Metrics

BasicAdvanced
$20.56B
Market cap
21.19
P/E ratio
$4.08
EPS
0.25
Beta
-
Dividend rate
$20.56B
0.24602
$131.52
$85.21
625.92K
9.431
9.258
0.943
1.082
7.321
4.02%
4.62%
4.51%
21.186
5.058
0.954
1.013
4.14
-77.94%
-89.89%
99.31%
299.76%

What the Analysts think about BioNTech SE

Analyst Ratings

Majority rating from 18 analysts.
Buy

Price Targets

Average projection from 16 analysts.
37.33% upside
High $170.17
Low $89.56
$86.48
Current price
$118.76
Average price target

BioNTech SE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
30.96% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
€1.48B
65.2%
Net income
€457.9M
185.12%
Profit margin
30.96%
72.67%

BioNTech SE Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 21.5%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
€2.05
-€0.79
€0.67
€1.90
-
Expected
€0.14
-€0.96
-€0.10
€2.42
-€1.08
Surprise
1,341.41%
-17.61%
-796.1%
-21.5%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

FAQs

What’s the current market cap for BioNTech SE stock?

BioNTech SE (BNTX) has a market cap of $20.56B as of April 14, 2024.

What is the P/E ratio for BioNTech SE stock?

The price to earnings (P/E) ratio for BioNTech SE (BNTX) stock is 21.19 as of April 14, 2024.

Does BioNTech SE stock pay dividends?

No, BioNTech SE (BNTX) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next BioNTech SE dividend payment date?

BioNTech SE (BNTX) stock does not pay dividends to its shareholders.

What is the beta indicator for BioNTech SE?

BioNTech SE (BNTX) has a beta rating of 0.25. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the BioNTech SE stock price target?

The target price for BioNTech SE (BNTX) stock is $118.76, which is 37.33% above the current price of $86.48. This is an average based on projections from 16 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell BioNTech SE stock

Buy or sell BioNTech SE stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing